Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Coumadin
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 77 results found since Jan 2013.
Perioperative Heparin Bridging in Atrial Fibrillation Patients Requiring Temporary Interruption of Anticoagulation: Evidence from Meta-analysis
Patients with atrial fibrillation (AF) often require temporary interruption of warfarin for an elective operation or invasive procedure. However, the safety and efficacy of periprocedural bridging anticoagulation with unfractionated heparin (UH) or low–molecular-weight heparin (LMWH) are still unclear. We evaluated the safety of periprocedural heparin bridging in AF patients requiring temporary interruption of oral anticoagulation.
Source: Journal of Stroke and Cerebrovascular Diseases - June 7, 2016 Category: Neurology Authors: Karam Ayoub, Ramez Nairooz, Ahmed Almomani, Meera Marji, Hakan Paydak, Waddah Maskoun Source Type: research
Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients —Analysis of Pharmaceuticals and Medical Devices Agency Data
Two forms of direct oral anticoagulant (DOAC) have recently been introduced: direct thrombin inhibitors (DTI; e.g., dabigatran) and factor Xa inhibitors (FXa; e.g., rivaroxaban and apixaban). Despite the advantages of DOACs over warfarin with regard to cerebrovascular complications, those associated with DOACs have been reported with the increasing use of DOACs. Nevertheless, little is known about real-world comparative efficacy and safety of DOACs.
Source: Journal of Stroke and Cerebrovascular Diseases - February 3, 2017 Category: Neurology Authors: Yasuo Terayama Source Type: research
Intracerebral hemorrhage under antithrombotic medication in a recent year
Antithrombotic medication will be a risk of hemorrhagic complication. Meanwhile, direct oral anticoagulants (DOACs), which are recently introduced in the clinical use, are reported to show lower risk of intracerebral hemorrhage (ICH) compared with warfarin. However, the severity at onset and the outcome of ICH patients with DOACs are still controversial. Therefore, this study aimed to reveal the clinical features of recent ICH patients with antithrombotic medication including DOACs.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Taizen Nakase, Tatsuya Ishikawa, Akifumi Suzuki Source Type: research
Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation
Warfarin has a narrow therapeutic window. We hypothesized that genetic factors related to warfarin metabolism (CYP2C9) and activity (VKORC1) would show stronger associations than modifiable factors with the quality of anticoagulation control and risks for thromboembolism and hemorrhage.
Source: Journal of Stroke and Cerebrovascular Diseases - April 13, 2017 Category: Neurology Authors: Yun Kyung Park, Mi Ji Lee, Jae Ha Kim, Jin Soo Lee, Rae Woong Park, Gyeong-Moon Kim, Chin-Sang Chung, Kwang Ho Lee, June Soo Kim, Soo-Youn Lee, Oh Young Bang Source Type: research
Intracerebral Hemorrhagic Expansion Occurs in Patients Using Non –Vitamin K Antagonist Oral Anticoagulants Comparable with Patients Using Warfarin
Non –vitamin K antagonist oral anticoagulant (NOAC) use has significantly reduced intracerebral hemorrhagic (ICH) risk compared with standard anticoagulant treatment. Hematoma expansion (HE) is a known predictor of mortality in warfarin-associated ICH. Little is known about HE in patients using NOACs.
Source: Journal of Stroke and Cerebrovascular Diseases - June 21, 2017 Category: Neurology Authors: Kara R. Melmed, Patrick Lyden, Norman Gellada, Asma Moheet Source Type: research
Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin
Direct oral coagulants (DOAC) have been shown to decrease the frequency of intracerebral hemorrhage (ICH) compared with warfarin. However, the precise characteristics, such as the size and locations of the hemorrhage, and outcome and onset time of ICH in patient taking DOAC are not fully elucidated.
Source: Journal of Stroke and Cerebrovascular Diseases - February 4, 2018 Category: Neurology Authors: Masahito Kawabori, Yoshimasa Niiya, Motoyuki Iwasaki, Shoji Mabuchi, Hiroyuki Ozaki, Koji Matsubara, Kiyohiro Houkin Source Type: research
Bilateral Cerebral Infarctions and Intracardiac Thrombus in a Young Duchenne Muscular Dystrophy Patient
A 31-year-old man with Duchenne muscular dystrophy was admitted to our center, having infarctions in bilateral cerebral hemispheres and an occluded right middle cerebral artery. His right middle cerebral artery was spontaneous recanalization on the next day, and thrombus in the left ventricle vanished on the eighth day after giving warfarin.
Source: Journal of Stroke and Cerebrovascular Diseases - March 20, 2018 Category: Neurology Authors: Yanan Qiao, Manabu Inoue, Muneaki Kikuno, Dantao Peng, Zunjing Liu, Kazunori Toyoda Tags: Case Studies Source Type: research
Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin
Direct oral coagulants (DOAC) have been shown to decrease the frequency of intracerebral hemorrhage (ICH) compared with warfarin. However, the precise characteristics, such as the size and locations of the hemorrhage, and outcome and onset time of ICH in patient taking DOAC are not fully elucidated.
Source: Journal of Stroke and Cerebrovascular Diseases - February 4, 2018 Category: Neurology Authors: Masahito Kawabori, Yoshimasa Niiya, Motoyuki Iwasaki, Shoji Mabuchi, Hiroyuki Ozaki, Koji Matsubara, Kiyohiro Houkin Source Type: research
Is Rivaroxaban a Safe Choice for Apical Thrombus in Atrial Fibrillation Patients? A Case Report
Left ventricular thrombi are mostly seen in the akinetic segments of left ventricle and warfarin is the golden standard treatment. In our case, a 67-year-old male patient with ischemic dilated cardiomyopathy and atrial fibrillation was under warfarin treatment, but due to fluctuations in international normalized ratio, warfarin was discontinued and changed to rivaroxaban (20 mg once a day). He had a fixed thrombus measuring 1.80 × 1.12 cm2 in the left ventricle under warfarin treatment before rivaroxaban use.
Source: Journal of Stroke and Cerebrovascular Diseases - May 4, 2018 Category: Neurology Authors: Fatih Aydin, Ozge Turgay Yildirim, Ayse Huseyinoglu Aydin, Evrin Dagtekin, Ercan Aksit Tags: Case Studies Source Type: research
Direct Oral Anticoagulant Agents: Pharmacologic Profile, Indications, Coagulation Monitoring, and Reversal Agents
Vitamin K antagonists (VKAs), such as warfarin, have been used for thromboprophylaxis and for the treatment of thromboembolic events in patients with nonvalvular atrial fibrillation for over 60 years. The increasing use of direct oral anticoagulants (DOACs) in recent years has shown greater advantages and safer use over VKA, including reduced bleeding, fewer drug interactions, no food interactions, a quick onset and offset of activity, and predictable dose-response properties. Despite their advantages, there are a couple of major limitations that raise concerns among clinicians, including the need for more coagulation assa...
Source: Journal of Stroke and Cerebrovascular Diseases - May 9, 2018 Category: Neurology Authors: Deborah K. Rose, Barak Bar Tags: Review Article Source Type: research
Interhospital Transfer Delays Anticoagulation Reversal in Warfarin-Associated Intracranial Hemorrhage
Intracranial hemorrhage (ICH) is a complication of warfarin-associated anticoagulation resulting in significant morbidity and mortality. The purpose of this study was to assess whether interhospital transfer delays the administration of 4-factor prothrombin complex concentrate to patients with warfarin-associated ICH.
Source: Journal of Stroke and Cerebrovascular Diseases - August 30, 2018 Category: Neurology Authors: Anne Zepeski, Stacey Rewitzer, Enrique C Leira, Karisa Harland, Brett A. Faine Source Type: research
Intracardiac Thrombus Following Rivaroxaban Treatment in a Patient with Atrial Fibrillation Associated with Rheumatic Heart Disease
We report a case of atrial fibrillation with rheumatic heart disease (RHD) who had intracardiac thrombus and cardiogenic cerebral embolism with rivaroxaban therapy. Intracardiac thrombus disappeared after switching from rivaroxaban to warfarin. Patients of RHD have the possibility of gradual progression of valvular disease even if they are old, so we need to distinguish nonvalvular atrial fibrillation from RHD before starting direct oral anticoagulants.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2019 Category: Neurology Authors: Hiroaki Ohara, Shiro Yamamoto, Keiko Nagano, Kazuo Hashikawa Tags: Case Report Source Type: research
Reversal strategies and outcomes in patients with atrial fibrillation and warfarin-associated intracranial hemorrhage
While anticoagulants are highly effective in preventing thromboembolism in atrial fibrillation (AF), they raise the risk of hemorrhage, which can be life-threatening especially in cases of intracranial hemorrhage (ICH). Warfarin-associated intraparenchymal hemorrhage (IPH) leads to death within 30 days in as many as 60% of cases while the other major category of ICH on warfarin, subdural hemorrhage (SDH), leads to death in approximately a quarter of cases.1 Managing these potentially devastating bleeds is an important consideration in treating patients on oral anticoagulant therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - July 15, 2020 Category: Neurology Authors: Daniel E. Singer, Leila H. Borowsky, Susan Regan, Jong Woo Lee, Kristina Zint, Lionel Riou Franca, Joshua N. Goldstein Source Type: research
